Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=-approved
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-approved", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-approved", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-approved", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=-approved" }, "data": [ { "type": "Grant", "id": "12349", "attributes": { "award_id": "1R01CA274450-01A1", "title": "Developing and Testing a Culturally Tailored Mobile Health and Social MediaPhysical Activity Intervention Among Adolescent and Young Adult ChildhoodCancer Survivors", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 28265, "first_name": "DAVID WORTH", "last_name": "Dean", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-21", "end_date": "2026-08-31", "award_amount": 431195, "principal_investigator": { "id": 24582, "first_name": "NINA S", "last_name": "KADAN-LOTTICK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 181, "ror": "https://ror.org/05vzafd60", "name": "Georgetown University", "address": "", "city": "", "state": "DC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 28266, "first_name": "Jason A", "last_name": "Mendoza", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 732, "ror": "https://ror.org/01njes783", "name": "Seattle Children's Hospital", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Latinx childhood cancer survivors have an increased risk of cardiometabolic dysfunction. While physical activity (PA) is associated with lower risk of cancer recurrence, cardiometabolic dysfunction, and higher quality of life, 57% of Latinx survivors are inactive. Culturally tailored interventions to increase PA for Latinx AYA survivors do not currently exist despite their urgent need. We will address this critical gap by efficiently leveraging the infrastructure in the Children’s Oncology Group (COG) created by our ongoing StepByStep randomized controlled trial (RCT; U01CA246665) that investigates a mHealth PA intervention in AYA childhood cancer survivors among English-speakers. Despite the COVID-19 pandemic, we have been successful in enrolling patients from COG, conducting assessments and intervention components remotely. Because the U01 StepByStep RCT is limited to English speakers, we propose (1) to apply a cultural centering process for behavioral interventions, using the general StepByStep intervention as a starting point, to create a novel intervention and (2) to test the resulting culturally tailored intervention in a short term efficacy RCT. We will efficiently extend our established study infrastructure within COG to recruit Latinx survivors who speak Spanish and/or English. In response to PAR-21-190 (Modular R01), we propose the following Specific Aims: 1. Use an iterative approach to develop a novel, culturally tailored multilevel remote-based physical activity intervention among 20 Latinx AYA childhood cancer survivors whose preferred language is Spanish or English. The iterative process will combine 3 rounds of testing of the intervention components alternating with qualitative interviews to obtain participant feedback to guide intervention modifications. 2. Conduct a RCT to test the novel culturally tailored remote-based physical activity intervention to demonstrate efficacy over 12 weeks among a separate group of 160 Latinx AYA childhood cancer survivors whose preferred language is Spanish or English (n=80 per randomization arm) and who do not meet PA guidelines. The control group will receive a Fitbit only. We will test the following hypotheses (H): H1: Intervention participants will have greater increases in moderate-to-vigorous PA (primary outcome) than controls as assessed by accelerometry. H2. Intervention participants will have greater improvements in cardiopulmonary fitness and resting heart rate than controls as assessed by the 2-minute step test and heart rate monitor (exploratory outcomes). H3: Intervention participants will have greater improvements in global, physical, and social functioning and fatigue than control patients as assessed by validated self-report instruments (exploratory outcomes). 3. Conduct two rounds of post-trial qualitative interviews, n=30 for the intensive intervention phase and n=30 for the maintenance intervention phase, to determine acceptability of and guidance on improving both intervention phases in preparation for a fully powered, longer term RCT.", "keywords": [ "Accelerometer", "Adolescent and Young Adult", "Age", "Behavior Therapy", "COVID-19 pandemic", "Cancer Control", "Cardiomyopathies", "Cardiopulmonary", "Chronic", "Communication", "Communities", "Control Groups", "Diet and Nutrition", "Dyslipidemias", "Enrollment", "Evaluation", "Fatigue", "Feedback", "Functional disorder", "Funding", "Future", "General Population", "Goals", "Guidelines", "Health", "Health behavior", "Heart Rate", "Infrastructure", "Instagram", "Insulin Resistance", "Intervention", "Intervention Studies", "Interview", "Language", "Late Effects", "Latinx", "Maintenance", "Malignant Neoplasms", "Modeling", "Modification", "Obesity", "Outcome", "Participant", "Patient Recruitments", "Patient Self-Report", "Patients", "Pediatric Oncology Group", "Phase", "Physical Function", "Physical activity", "Population Sciences", "Preparation", "Privatization", "Process", "Quality of life", "Randomized", "Randomized Controlled Trials", "Recommendation", "Recurrent Malignant Neoplasm", "Reporting", "Research", "Rest", "Risk", "Site", "Social Functioning", "Step Tests", "Support Groups", "Survivors", "Target Populations", "Test Result", "Testing", "Time", "Treatment Efficacy", "arm", "cancer complication", "cancer recurrence", "cancer risk", "cancer therapy", "cardiometabolic risk", "cardiometabolism", "cardiovascular health", "childhood cancer survivor", "curative treatments", "efficacy testing", "exercise intervention", "fitbit", "fitness", "health related quality of life", "heart rate monitor", "improved", "innovation", "instrument", "intervention participants", "mHealth", "moderate-to-vigorous physical activity", "novel", "outcome disparities", "participant enrollment", "peer support", "portability", "predictive marker", "preference", "prevent", "primary outcome", "recruit", "response", "sedentary", "social", "social media", "systematic review", "therapy development", "virtual" ], "approved": true } }, { "type": "Grant", "id": "12350", "attributes": { "award_id": "1F31HL170550-01", "title": "The Respiratory Microbiome in COVID-19: Associations with Severity, Risk Factors, and Host Pathways", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26342, "first_name": "MARISOL", "last_name": "Espinoza-Pintucci", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-30", "end_date": null, "award_amount": 47694, "principal_investigator": { "id": 28267, "first_name": "Carter", "last_name": "Merenstein", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID-19 has caused unprecedented loss of life and global disruption since its emergence in 2019. Caused by the SARS CoV-2 virus, this infection shows extreme heterogeneity, ranging from completely asymptomatic to deadly. One factor that has been linked to COVID-19 severity is the microbiome of the upper respiratory tract, specifically the oropharynx. Lower relative abundance of oral commensal taxa, such as Haemophilus, Neisseria, Prevotella, and Actinomyces, and lower alpha diversity are seen in severe COVID-19 patients compared to individuals with more moderate disease. The mechanism of this association is still unknown, and it is unclear in which direction causation occurs. We propose to further examine the association between the respiratory microbiome and COVID-19 by 1) increasing specificity of these associations to the species, strain, and gene level, 2) identifying how comorbidities shape the respiratory microbiome prior to SARS CoV-2 infection, and 3) identifying host pathways that may be involved in these associations. For this first aim, we will leverage a cohort of over 200 hospitalized COVID-19 patients (previously enrolled and specimens already in hand), using deep metagenomic sequencing for taxonomic and functional annotation. The increased specificity provided by this aim will pave the way for in vitro or animal model experiments, which require species or strain level associations for proper experimental design. The second aim will focus on respiratory tract microbiome profiles in individuals with obesity, diabetes, or old age (who do not and have not had COVID-19), three conditions that are strongly associated with elevated risk of severe COVID-19. The effect that these have on the respiratory microbiome is unknown, but one still untested possibility is that the microbiome mediates some of the effects of these conditions on disease severity. By studying microbiome alterations in these diseases prior to SARS CoV-2 infection we could identify a potential high risk microbiome that precedes severe COVID- 19. Finally, the third aim pulls data from a diverse set of databases to create a knowledge graph of microbe- disease-gene associations. Using knowledge graph completion, we will predict host genes that both associate with COVID-19 severity, and interact with bacteria in the upper airway. With this data, we can propose possible host mechanisms that mediate microbiome-COVID-19 associations, allowing for in vitro follow-up to move from correlation to causation. Ultimately, this work is a bridge between existing high level associations between COVID-19 and the upper respiratory microbiome, and future work targeting specific mechanisms and causal links. Having recently published a review on all studies of the airway microbiome in COVID-19, we believe that these aims address the most critical gaps in understanding currently in the literature.", "keywords": [ "2019-nCoV", "ACE2", "Acceleration", "Actinomyces", "Address", "Affect", "Age", "Animal Model", "Antibiotics", "Bacteria", "COVID-19", "COVID-19 impact", "COVID-19 patient", "COVID-19 risk", "COVID-19 severity", "Cessation of life", "Clinical", "Data", "Databases", "Development", "Diabetes Mellitus", "Disease", "Disease Outcome", "Enrollment", "Etiology", "Experimental Animal Model", "Experimental Designs", "Future", "Gene Expression", "Genes", "Graph", "Hand", "Hemophilus", "Heterogeneity", "Hospitalization", "Immune", "Immune response", "In Vitro", "Individual", "Infection", "Interferon Type II", "Life", "Link", "Literature", "Lung diseases", "Lung infections", "Machine Learning", "Manuals", "Mediating", "Methods", "Microbe", "Neisseria", "Obesity", "Oropharyngeal", "Outcome", "Pathway interactions", "Patients", "Phenotype", "Prevotella", "Publishing", "Respiratory Disease", "Respiratory Failure", "Respiratory System", "Respiratory Tract Infections", "Risk", "Risk Factors", "SARS-CoV-2 infection", "Sampling", "Severities", "Severity of illness", "Shapes", "Specificity", "Specimen", "Stratification", "Symptoms", "Taxonomy", "Techniques", "Uncertainty", "Upper respiratory tract", "Validation", "Viral", "Virus", "Virus Diseases", "Work", "cell type", "clinical phenotype", "cohort", "comorbidity", "coronavirus disease", "cytokine", "cytokine release syndrome", "dysbiosis", "experimental study", "follow-up", "high risk", "host microbiome", "host-associated microbial communities", "host-microbe interactions", "human old age (65+)", "immunoregulation", "knowledge graph", "metagenomic sequencing", "microbiome", "microbiome alteration", "microbiome composition", "microbiome research", "morphogens", "multiple data types", "oral commensal", "pathogen", "protein protein interaction", "public database", "respiratory microbiome", "severe COVID-19", "superinfection", "supplemental oxygen", "synergism", "tool", "transcriptome sequencing" ], "approved": true } }, { "type": "Grant", "id": "12351", "attributes": { "award_id": "1R61DA059889-01", "title": "Methadone Patient Access to Collaborative Treatment (MPACT)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 26972, "first_name": "SEAN EDWARD WINTERS", "last_name": "Lynch", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-30", "end_date": "2025-08-31", "award_amount": 490522, "principal_investigator": { "id": 28268, "first_name": "Beth", "last_name": "Meyerson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 438, "ror": "https://ror.org/03m2x1q45", "name": "University of Arizona", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "Methadone Patient Access to Collaborative Treatment (MPACT) is a staff-level trauma-informed practice change intervention for US opioid treatment programs (OTP). It is based on the theory that current OTP practice and culture likely contribute to the wide ranging methadone maintenance treatment (MMT) interruption (>30%) and relapse (>50%) rates known to increase opioid overdoses. OTP treatment culture has been described as “carceral,” and “not healthcare,” with patients reporting being bound to the clinic by required daily supervised medication dosing. Changes in OTP practices have been called for, but are recognized as ‘almost impossible.’ US federal regulatory flexibilities intended to facilitate OTP practice change during COVID did not result in wide-spread or sustained MMT delivery changes or service accommodations such as increased multi-day dosing for stable patients, less frequent urine analyses, or even telehealth. These accommodations would be highly beneficial to rural and home-bound patients. Evidence- based OTP practice change interventions are necessary if the US is going to effectively respond to the opioid overdose crisis. If this lifesaving treatment is available but not well used, we must look to the practice and culture of OTPs. Lack of practice change may be due to staff beliefs and experiences, including their own histories of substance use disorder treatment, traumatic experiences, and on-the-job exposure to vicarious trauma. When staff trauma is addressed, we expect OTP practice orientation will shift from punitive to harm-reduction/patient-centered. MPACT is designed to increase MMT retention and decrease in-treatment overdose and patient- and staff- reported posttraumatic stress symptoms (PTSS). MPACT has four evidence-based components: 1) a 4-module CME/CEU- accredited trauma-informed psychoeducation training program for OTP staff, 2) a trauma navigation model for patients and staff, 3) clinic trauma-informed care (TIC) self-assessment, and 4) separate reflective supervisory structures for counselors/case managers and medical providers. For this proposal, MPACT components will be adapted for OTP settings with patients and providers in a multilevel, trauma-informed planning process with guidance from the Arizona transdisciplinary Drug Policy Research and Advocacy Board comprised of methadone and buprenorphine providers, patients, people with lived/ing drug use experience, harm reduction NGOs, payers, trauma experts, and university researchers. MPACT will be finalized in year 1, pilot tested and refined in year 2, and tested in a cluster-randomized controlled intervention trial in OTP sites across the US in years 3-6. The primary means of gathering data are surveys pushed to staff and patients (baseline and monthly) and retrospective patient chart reviews. We enter a period of unprecedented regulatory change for MMT delivery. MPACT can facilitate and support MMT reform efforts that are planned or already in process. The future of OTPs and methadone treatment depend upon evidence-based OTP practice change interventions. The pivotal question is: Can OTPs adopt Trauma Informed Care (TIC) and, if so, does it improve patient outcomes? MPACT seeks to answer this question in a high risk/high reward proposal. If the answer is YES, then MPACT will be immediately implementable and scalable for any OTP in the US.", "keywords": [ "Accreditation", "Address", "Adopted", "Adoption", "Advocacy", "Affect", "Arizona", "Belief", "Binding", "Buprenorphine", "Caring", "Case Manager", "Clinic", "Counseling", "Data", "Dose", "Drug usage", "Exposure to", "Future", "Harm Reduction", "Health Personnel", "Healthcare", "Hepatitis C virus", "Hybrids", "Interruption", "Intervention", "Intervention Trial", "Life", "Liquid substance", "Measurement", "Measures", "Medical", "Methadone", "Modeling", "Occupations", "Opioid replacement therapy", "Outcome", "Overdose", "Overdose reduction", "Patient-Focused Outcomes", "Patients", "Persons", "Pharmaceutical Preparations", "Policy Research", "Preparation", "Process", "Professional counselor", "Provider", "Randomized", "Randomized Controlled Trials", "Recording of previous events", "Regulation", "Relapse", "Reporting", "Research", "Research Personnel", "Risk", "Rural", "Sampling", "Self Assessment", "Self Care", "Services", "Site", "Stigmatization", "Structure", "Substance Use Disorder", "Surveys", "Testing", "Theory of Change", "Time", "Training", "Training Programs", "Trauma", "Trauma patient", "Treatment Protocols", "Universities", "Urine", "community based research", "coronavirus disease", "design", "effectiveness outcome", "efficacy evaluation", "empowerment", "evidence base", "experience", "flexibility", "high reward", "high risk", "implementation fidelity", "implementation outcomes", "improved", "innovation", "maltreatment", "member", "methadone patient", "methadone treatment", "opioid overdose", "opioid treatment program", "opioid use disorder", "patient oriented", "pilot test", "post-traumatic symptoms", "primary outcome", "psychoeducation", "psychoeducational", "recruit", "response", "retention rate", "success", "telehealth", "theories", "therapy design", "treatment effect", "treatment program" ], "approved": true } }, { "type": "Grant", "id": "12352", "attributes": { "award_id": "1U18HS029924-01", "title": "The Pitt IMProving Access to Culturally relevant long COVID care and Treatment (IMPACCT) Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 28197, "first_name": "Leeann", "last_name": "Comfort", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-30", "end_date": "2028-09-29", "award_amount": 979933, "principal_investigator": { "id": 28269, "first_name": "HOWARD B", "last_name": "DEGENHOLTZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28270, "first_name": "Alison", "last_name": "Morris", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28271, "first_name": "FRANK", "last_name": "SCIURBA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Long COVID encompasses a wide range of persistent symptoms and complications that impair quality of life and functioning of affected individuals. Few disease-specific treatment options are available, and evidence- based guidelines and comprehensive care models are lacking. The University of Pittsburgh Medical Center (UPMC) Long COVID clinic has developed a personalized strategy to address the wide variation in present- ation within the over 1,100 patients evaluated to date, yet many long COVID patients in our region lack access to providers with knowledge to diagnose, evaluate, and treat long COVID. To address this need, we will partner with UPMC Family Medicine Academic Clinic Practice and the Black Equity Coalition (BEC) to establish the Pitt IMProving Access to Culturally relevant long COVID care and Treatment (IMPACCT) Program in order to train the next generation of community providers in long COVID care and improve access to primary and specialty care for long COVID patients from underserved and rural populations. In Aim 1, we will expand healthcare provider capacity through the development of comprehensive, culturally informed educational materials and targeted outreach programs including developing diagnostic and treatment algorithms for major symptom clusters and introducing in-person lectures and web-based learning modules. Aim 2 provides expanded and equitable access to specialized long COVID care by establishing pathways for clinician-to-clinician e-consults and patient telemedicine or in-person visits in the Long COVID clinic, establishing point-of-care pulmonary function testing in each office, maximizing patient experience with a dedicated patient navigator and funds for travel to the clinic, facilitating telemedicine, and expanding our learning health care system for rapid review and implementation of emerging long COVID therapies. Aim 3 empowers long COVID patients by establishing a dedicated support group, a knowledge-sharing platform for community engagement and education, and providing patient resources for self-management. Finally, Aim 4 creates a comprehensive evaluation approach to monitor the effectiveness of the IMPACCT program, track patient outcomes, and identify areas for improvement. We anticipate that this four-pronged approach will lead to improved recognition, diagnosis, and management of long COVID, especially among underserved populations. All programs will be developed in partnership with the BEC, a Black-led group of physicians, researchers, epidemiologists, public health experts, community funders, and government officials, who will provide input on culturally relevant care and social determinants of health to ensure an equitable approach in care, as well as assistance with patient education and public relations. By uniting a multi-disciplinary group of investigators with expertise in long COVID care, healthcare delivery, implementation science, and evaluation strategies with community and academic organizations with a history of engagement of minority and underserved populations, this project will offer an innovative model to address health inequities and improve patient outcomes in our community and beyond.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12353", "attributes": { "award_id": "1R01MD019033-01", "title": "Addressing durable health disparities through critical time legal interventions in medically underserved Latinx and migrant communities in the United States.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 22601, "first_name": "Sundania J W", "last_name": "Wonnum", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-22", "end_date": "2028-03-31", "award_amount": 811991, "principal_investigator": { "id": 24253, "first_name": "MIGUEL A", "last_name": "MUNOZ-LABOY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1445, "ror": "", "name": "TEMPLE UNIV OF THE COMMONWEALTH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24254, "first_name": "Omar", "last_name": "Martinez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28273, "first_name": "Souhail M", "last_name": "Malave-Rivera", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28274, "first_name": "Carlos Emanuel", "last_name": "Rodriguez-Diaz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1415, "ror": "", "name": "STATE UNIVERSITY NEW YORK STONY BROOK", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Intersecting epidemics such as cardio-vascular conditions (e.g., hypertension), communicable diseases (e.g., COVID-19, HIV), metabolic conditions (e.g., diabetes), mental health and substance use disorders (e.g., co- occurring alcohol use disorder and depression) have tested the limits of healthcare systems in historically marginalized communities such as Latinx and migrant populations in the United States. The early detection and severity of the above conditions in medically underserved communities are aggravated by systemic barriers to primary care and detention. In this study, we proposed that providing legal services within primary care can enhance healthcare delivery efficiency through addressing legal needs (such as barriers to health insurance, medical treatments, housing safety, employment stability, and other legal needs) that can disrupt care to patients. The proposed study, led by the SBU School of Social Welfare and SBU Center for Changing Systems of Power, together with the GWU School of Public Health's Gill-Lebovic Center for Community Health in the Caribbean and Latin America, the University of Puerto Rico's Social Determinants Center, the National Center for Medical Legal Partnerships, UCF School of Medicine's Implementation Science Lab, and six federally qualified health centers; will precisely examine the effects of legal services on primary care outcomes for medically underserved communities. We will conduct a hybrid type II effectiveness-implementation trial with a cluster randomized design in 6 federally qualified health centers (FQHCs) in Orlando, FL, New York/Long Island, NY and San Juan, PR to test a Critical-time Intervention Medical Legal Partnership (CTI-MLP) approach compared to the standard of care. Three FQHCs will receive a CTI-MLP approach that includes provision of legal aid and capacity building through team-facing legal support. The other three FQHCs will receive legal education and awareness, including information about community-based legal organizations. Over a 12-month period, the team will collect (1) patients' health and functioning, including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life; (2) data on legal needs and risk factors (3) longitudinal patient clinical outcomes (N=960); and (4) FQHC staff (N=180) and clinic-level indicators, including provider-patient communication and readiness for continued implementation and sustainability. We will assemble a Latinx and migrant community advisory board and a scientific advisory board with medical-legal partnership expertise. Active engagement will ensure the effective translation and dissemination of our findings into practice. With new Medicaid models emerging that offer reimbursement for some social care provision, state officials can also use data to consider expansion of Medicaid services to include the coordination and provision of social and legal services. Completion of this project will result in an innovative, evidence-based intervention package to improve health outcomes for highly vulnerable communities.", "keywords": [ "Address", "Affect", "Asthma", "Award", "Awareness", "COVID-19", "Cardiovascular system", "Caribbean region", "Caring", "Clinic", "Clinical", "Communicable Diseases", "Communities", "Community Health", "Consolidated Framework for Implementation Research", "Continuity of Patient Care", "Costs and Benefits", "Data", "Development", "Diabetes Mellitus", "Disability Insurance", "Discrimination", "Domestic Violence", "Early Diagnosis", "Education", "Employment", "Ensure", "Epidemic", "Evidence based intervention", "Fatigue", "Federally Qualified Health Center", "Food Access", "Gills", "HIV", "Health", "Health Insurance", "Health Services", "Healthcare", "Healthcare Systems", "Heart Diseases", "Housing", "Hybrids", "Hypertension", "Individual", "Insurance", "Insurance Coverage", "Intervention", "Latin America", "Latino", "Latinx", "Lead", "Legal", "Legal Intervention", "Long Island", "Low income", "Medicaid", "Medicaid services", "Medical", "Medical center", "Mental Depression", "Mental Health", "Metabolic", "Migrant", "Modeling", "Neighborhood Health Center", "New York", "Outcome", "Pain", "Patient-Focused Outcomes", "Patients", "Perceived quality of life", "Persons", "Population", "Primary Care", "Public Health Schools", "Puerto Rico", "Reach Effectiveness Adoption Implementation and Maintenance", "Readiness", "Recovery", "Reduce health disparities", "Reporting", "Research Personnel", "Resources", "Risk Factors", "Safety", "Schools", "Service delivery model", "Services", "Severities", "Social Welfare", "Substance Use Disorder", "System", "Testing", "Time", "Translations", "United States", "United States National Institutes of Health", "Universities", "Work", "Workplace", "alcohol use disorder", "arm", "barrier to care", "care outcomes", "cluster randomized design", "community engagement", "cost effective", "effectiveness testing", "effectiveness/implementation trial", "enhancing factor", "experience", "food security", "global health", "health care delivery", "health care service", "health disparity", "health equity", "health inequalities", "implementation outcomes", "implementation science", "implementation strategy", "improved", "innovation", "marginalization", "marginalized community", "marginalized population", "medical schools", "medically underserved", "medically underserved population", "migration", "patient-clinician communication", "physical co" ], "approved": true } }, { "type": "Grant", "id": "12354", "attributes": { "award_id": "1R21AA031377-01", "title": "A Qualitative Analysis of Social and Behavioral Processes Associated with Self-Change in Drinking in an Existing Cohort of Black and White Emerging Adults", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" ], "program_reference_codes": [], "program_officials": [ { "id": 26558, "first_name": "Bradley Townsend", "last_name": "Kerridge", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-15", "end_date": "2025-08-31", "award_amount": 180500, "principal_investigator": { "id": 28275, "first_name": "JAMES", "last_name": "MACKILLOP", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28276, "first_name": "JAMES G.", "last_name": "MURPHY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 694, "ror": "https://ror.org/01cq23130", "name": "University of Memphis", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "In the United States, emerging adults (EAs, ages 18-29) consume alcohol at higher rates than people in any other age group, and the number and rate of alcohol-related deaths increased approximately 25% during the first two years of the COVID-19 pandemic. Black EAs and EAs who are not graduates of four-year colleges experience greater consequences from alcohol use and have been identified as an understudied, high-priority group by both NIAAA and the US Institute of Medicine. Funded by NIAAA, we have followed a diverse community-based cohort of 601 emerging adults since 2017 (mean age at inception = 22.5; 47% White, 42% Black; 35% without a college degree). Phase one of Project BETA was the first to carefully examine behavioral economic predictors of alcohol use trajectories in the mid-twenties and has generated 34 publications and supported 4 funded secondary grants. We recently completed data collection and have identified subgroups of emerging adults who have (1) reduced their drinking since becoming involved with the study and report consistent low-risk drinking over the past year based on the WHO Classification (N = 281) or (2) increased drinking or been relatively persistent high-risk drinkers throughout the course of study (as defined by the WHO Classification; N = 174). The proposed R21 will leverage these existing subgroups by having 40 participants from each of these subgroups (50% of participants enrolled will be Black) view a summary of their individual drinking trajectories throughout their 3.5-year participation in the parent study to facilitate a discussion of potentially modifiable factors associated with self- change or persistent risky drinking, including behavioral economic variables and experiences of discrimination. In addition to gaining an understanding of how participants successfully changed their drinking, our interviews and qualitative analyses will also gain insights into how to design and disseminate prevention and intervention programs to reduce alcohol risk for diverse community-residing emerging adults. We will obtain feedback on preferred intervention content, modalities, and locations/venues. Our team includes experts in emerging adult alcohol misuse, addiction and recovery, brief interventions, qualitative methods, and cultural adaptation of alcohol treatments for Black Americans and is thus ideally suited to successfully complete these aims and to use the results to develop and refine effective, culturally informed alcohol prevention approaches with high potential for dissemination in community settings in a subsequent R01 application.", "keywords": [ "Address", "Age", "Alcohol abuse", "Alcohol consumption", "Alcohols", "Attention", "Behavioral", "Black American", "Black race", "COVID-19 pandemic", "COVID-19 pandemic effects", "Classification", "Communities", "Coronavirus", "Data", "Data Collection", "Development", "Drug usage", "Economics", "Education", "Enrollment", "Feedback", "Female", "Funding", "Goals", "Grant", "Health", "Home", "Individual", "Informal Social Control", "Institute of Medicine (U.S.)", "Intervention", "Interview", "Knowledge", "Life", "Location", "Longitudinal Studies", "Modality", "Morbidity - disease rate", "National Institute on Alcohol Abuse and Alcoholism", "Outcome", "Parents", "Participant", "Persons", "Pharmaceutical Preparations", "Phase", "Prevalence", "Prevention", "Prevention approach", "Prevention program", "Process", "Public Health", "Publications", "Qualitative Methods", "Qualitative Research", "Recovery", "Reporting", "Research", "Rewards", "Risk", "Risk Factors", "Social support", "Source", "Stress", "Subgroup", "United States", "addiction", "age group", "alcohol abuse therapy", "alcohol consequences", "alcohol misuse", "alcohol prevention", "alcohol risk", "alcohol risk reduction", "alcohol-related death", "behavioral economics", "binge drinking", "brief intervention", "cohort", "college", "community setting", "comorbidity", "design", "drinking", "emerging adult", "emerging adulthood", "evidence base", "experience", "help-seeking behavior", "high risk", "high risk drinking", "high risk population", "insight", "intervention program", "modifiable risk", "mortality", "pandemic disease", "pandemic impact", "pandemic stress", "participant enrollment", "perceived discrimination", "preventive intervention", "protective factors", "racial population", "social", "substance use", "systemic barrier", "trend" ], "approved": true } }, { "type": "Grant", "id": "12355", "attributes": { "award_id": "1R01MH135477-01", "title": "Investigation of Digital Media Use, Anxiety, and Biobehavioral Emotion Regulation in Adolescents", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 28277, "first_name": "Laura A.", "last_name": "Thomas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-08", "end_date": "2028-06-30", "award_amount": 692172, "principal_investigator": { "id": 28278, "first_name": "Sarah C", "last_name": "Myruski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 833, "ror": "", "name": "PENNSYLVANIA STATE UNIVERSITY, THE", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Anxiety symptom onset peaks in adolescence, with an estimated one in three teens experiencing clinically-significant symptoms by age 18 years. Adolescent anxiety confers risk for adulthood anxiety disorders, as well as poor outcomes in multiple domains including overall health and interpersonal functioning. Over the past several decades, the social world of teens has been transformed by pervasive use of digital media (e.g., social media, messaging apps) ingrained in daily life. Both adolescent anxiety and digital media use have continued to become increasingly prevalent throughout the COVID-19 pandemic, highlighting the urgent need for rigorous investigations of longitudinal and mechanistic links between digital technology use and mental health. Guided by three major gaps in the literature, the proposed study will (1) capture how youth engage in digital media use in ways that facilitate or disrupt social connectedness, (2) examine when youth use digital media in the context of momentary affect and anxiety in daily life, and (3) address why digital media use may be beneficial or detrimental for some by examining mechanistic links among biobehavioral cognitive and affective functioning, digital media use, and anxiety. In particular, adolescence is a critical period of neurodevelopment in frontal-subcortical circuitry underlying emotion regulation, the implicit and explicit processes by which we manage emotions, and a major predictor of anxiety disorders. This study will leverage an innovative, multi-method (i.e., questionnaires, interviews, reaction time, eye-tracking, EEG) biobehavioral assessment of emotion regulation coupled with ecological momentary assessment (EMA) of within-person daily patterns of digital media use, emotional experiences, anxiety symptoms, and emotion regulation measured longitudinally in teens. We will index youths' emotion regulation strengths and vulnerabilities by (1) contextualizing emotion regulation within adolescents' daily life, (2) targeting both explicit and implicit regulatory processes, and (3) capturing biobehavioral aspects of ER that reflect rapid attentional processes, cognitive control, and flexibility. This work is in line with the Research Domain Criteria initiative to investigate developmental change within ecologically-valid environments by integrating measurement across multiple domains [(negative valence (potential threat), cognitive systems (attention, control), social processes (communication, connectedness), arousal (affective states)] and across units of analysis (physiology, behaviors, paradigms, self-reports). This research aligns with the NIH-wide strategic plan emphasizing the need to illuminate the role of technology and media use in development and will contribute to NIMH's Objective 2 by furthering the interrogation of biobehavioral indicators related to anxiety symptom trajectories in youth. Findings from this research have the potential to elucidate the impact of digital media use on vulnerable individuals and inform recommendations for healthy technology use.", "keywords": [ "18 year old", "Address", "Adolescence", "Adolescent", "Adult", "Affect", "Affective", "Age", "Anxiety", "Anxiety Disorders", "Arousal", "Attention", "Behavior", "Biological", "COVID-19 pandemic", "Cognitive", "Communication", "Compensation", "Computers", "Coupled", "Data", "Development", "Devices", "Ecological momentary assessment", "Electroencephalography", "Emotions", "Environment", "Face", "Female", "Fostering", "Frequencies", "Habits", "Health", "Impairment", "Individual Differences", "Instagram", "Interview", "Investigation", "Life", "Link", "Literature", "Measurement", "Measures", "Mediating", "Mental Health", "Methodology", "Methods", "National Institute of Mental Health", "Negative Valence", "Neurocognitive", "Outcome", "Participant", "Patient Self-Report", "Pattern", "Perception", "Persons", "Physiology", "Prevalence", "Process", "Psychopathology", "Psychophysiology", "Questionnaires", "Reaction Time", "Recommendation", "Reporting", "Research", "Research Domain Criteria", "Rest", "Risk", "Role", "Sampling", "Sex Differences", "Social Behavior", "Social Change", "Social Processes", "Strategic Planning", "Symptoms", "Technology", "Teenagers", "Time", "United States National Institutes of Health", "Variant", "Vulnerable Populations", "Work", "Youth", "anxiety symptoms", "attentional bias", "biobehavior", "childhood anxiety", "clinically significant", "cognitive control", "cognitive system", "critical period", "design", "digital media", "digital technology", "emotion regulation", "emotional experience", "experience", "flexibility", "handheld mobile device", "indexing", "infancy", "innovation", "longitudinal design", "male", "negative affect", "neurodevelopment", "physical conditioning", "preference", "recruit", "rumination", "showing emotion", "social", "social media", "visual tracking" ], "approved": true } }, { "type": "Grant", "id": "12356", "attributes": { "award_id": "1UG1CA284671-01", "title": "CAPRISA CASCADE Clinical Trials Network Clinical Research Site", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 28279, "first_name": "MARIA SILVINA", "last_name": "Frech", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-05", "end_date": "2027-05-31", "award_amount": 216000, "principal_investigator": { "id": 28280, "first_name": "Nivashnee", "last_name": "Naicker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1210, "ror": "", "name": "CENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA", "address": "", "city": "", "state": "", "zip": "", "country": "SOUTH AFRICA", "approved": true }, "abstract": "The Center for the AIDS Program of Research in South Africa (CAPRISA) CASCADE Clinical Trials Network Clinical Research Site, aims to provide clinical trial infrastructure and operational leadership for the conduct of pragmatic clinical trials through the CASCADE Clinical Trials Network. The proposed clinical trial site is strategically located in KwaZulu-Natal (KZN) province, the epicentre of the Human Immunodeficiency Virus (HIV) epidemic in South Africa. Due to the high background HIV prevalence in this setting, KZN province remains a region with a high burden of cervical cancer disease, despite expansion and improved access to antiretroviral treatment (ART). CAPRISA has been undertaking high-impact globally relevant and locally responsive research for nearly two decades. The Ethekwini Clinical Research Site (ECRS) is one of four clinical research sites and is based in the central business district in Ethekwini. This is a well-established research site, with over 15 years’ experience conducting high-quality clinical trials. We have established research infrastructure which supports the conduct of both CAPRISA-led research as well as National Institutes of Health (NIH) network- affiliated trials, primarily recruiting young women for participation in our trials. To date, our core focus of research has been HIV prevention, although we are equally experienced in research involving HIV pathogenesis and clinical management of women living with HIV (WLHIV). Together with previous Human Papilloma Virus (HPV) epidemiological studies undertaken by our team, we have begun preliminary work in cervical cancer screening in an ongoing CAPRISA trial, where we are evaluating HPV point-of-care testing in WLHIV. Through the CASCADE network we aim to support and advance cervical cancer prevention, through participation in clinical trials. Through our relevant clinical trial experience and scientific expertise, we are able to contribute to the four scientific focus areas proposed by the network: increasing screening uptake, improving management of screen positives, facilitating precancer treatment access and optimising precancer treatment for cervical cancer prevention in WLHIV. We have assembled a strong team of investigators to support this program, including a Principal Investigator (PI) and Co-Investigators who have led multiple HIV and COVID-19 clinical trials at a site level and are leading several NIH-funded protocols as national PIs or protocol co-Chairs. The team are able to contribute to protocol development and to provide laboratory, data management and statistical support for trials undertaken through the network. Furthermore, we are able to collaborate with the respective research bases and coordinating centers proposed by the network. Considering CAPRISA’s expertise in HIV research and preliminary work undertaken in HPV epidemiology and HPV diagnostics, we are well-placed to be a strong partner in the CASCADE network.", "keywords": [ "AIDS prevention", "Acceleration", "Acquired Immunodeficiency Syndrome", "African", "Aftercare", "Age", "Area", "Businesses", "CD4 Lymphocyte Count", "COVID-19", "Cancer Etiology", "Cervical", "Cervical Cancer Screening", "Cervical Smears", "Cervix Uteri", "Clinical", "Clinical Management", "Clinical Research", "Clinical Trials", "Clinical Trials Network", "Collaborations", "Colposcopy", "Communities", "Cytology", "Data", "Diagnostic", "Disease", "Educational Status", "Epidemic", "Epidemiology", "Evaluation", "Feasibility Studies", "Female", "Funding", "Goals", "HIV", "HIV Infections", "HIV Vaccine Trials Network", "HIV vaccine", "HPV-High Risk", "Health Services Accessibility", "Healthcare Systems", "High Prevalence", "Household", "Human Papilloma Virus Vaccination", "Human Papillomavirus", "Human papilloma virus infection", "Improve Access", "Incidence", "Infection", "Infrastructure", "International", "Intervention", "Laboratories", "Leadership", "Lesion", "Malignant Neoplasms", "Malignant neoplasm of cervix uteri", "Oncogenic", "Outcome", "Participant", "Pathogenesis", "Population", "Pragmatic clinical trial", "Pregnant Women", "Prevalence", "Prevention program", "Prevention strategy", "Principal Investigator", "Protocols documentation", "Province", "Public Sector", "Recommendation", "Recurrence", "Reporting", "Research", "Research Infrastructure", "Research Personnel", "Risk", "Schools", "Secondary Prevention", "Services", "Sexually Transmitted Diseases", "Site", "South Africa", "Surveys", "Testing", "United States National Institutes of Health", "Woman", "Work", "World Health Organization", "ablative procedure", "aged", "antenatal", "antiretroviral therapy", "base", "cancer diagnosis", "cervical cancer prevention", "clinical research site", "clinically relevant", "clinically significant", "co-infection", "cohort", "data management", "epidemic virus", "epidemiology study", "experience", "follow-up", "improved", "insight", "mortality", "novel", "point of care testing", "premalignant", "programs", "protocol development", "recruit", "screening", "sex", "treatment optimization", "treatment program", "uptake", "young woman" ], "approved": true } }, { "type": "Grant", "id": "12357", "attributes": { "award_id": "1R43IP001228-01", "title": "PA-21-259, SBIR, Phase I, Self-Amplifying RNA Replicon-Based Platform for Generating Multivalent Influenza Vaccine", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-30", "end_date": "2024-09-29", "award_amount": 263991, "principal_investigator": { "id": 28281, "first_name": "Valerian", "last_name": "Nakaar", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2088, "ror": "", "name": "CAROGEN CORPORATION", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "Current vaccines are mainly strain-specific and have limited efficacy in preventing new, potentially pandemic influenza strains. Interest in a universal influenza vaccine (UIV) to prevent future pandemics has been greatly boosted by the success of mRNA-based coronavirus vaccines. However, developing a UIV has been particularly challenging for two reasons: (1) the failure of immunization to induce broadly neutralizing antibodies against conserved epitopes and (2) the lack of a safe and effective vaccine platform to induce broad and long-lasting immunity. Virus-like vesicles (VLVs) are infectious, self-propagating alphavirus-vesiculovirus hybrid vaccine vectors that can be engineered to express foreign antigens to elicit a protective immune response. These self-amplifying RNA replicons are safe, highly immunogenic, and scalable to produce. The goal of this proposal is to rationally design and engineer a VLV to express multiple flu antigens and thus induce broad and long-lasting immunity. As shown in our published studies, the ectodomain of M2 (M2e) and domains of the immunodominant hemagglutinin (HA) globular head can elicit robust antibody responses that mitigate disease and protect mice from lethal challenge. We have also established that VLV carrying RNA encoding one or more of the major antigens of hepatitis B virus (HBV) in a single open reading frame drives a broad multi-specific immune response that results in substantial clearance of HBV in the mouse liver. Recent improvements in the development of this VLV immunotherapy vector enhanced gene expression with a concomitant increase in both T-cell responses and antibodies. In preliminary studies, we found that signal sequences promote efficient secretion of recombinant proteins that are highly conserved among influenza strains, i.e., M2e, nucleoprotein, the long-alpha helix (LAH) of subunit 2 of HA, and fusion peptide from VLV-infected cells. Our initial single-dose screening of individual flu antigen VLV vaccines (sponsored by the Respiratory Diseases Branch of NIAID/NIH) showed promising mitigation of disease progression. A reduction in lung virus titer was apparent in HA2 VLV vaccines. Albeit low, viral neutralizing titers (VNTs) were present in all immunized groups (>1:16). In addition, our serological data show an increased induction of IgG1 and IgG2a in most flu-based VLV-immunized groups. These virus-specific IgG isotypes correlate better with vaccine efficacy than neutralization alone. We will carry out three specific aims: Aim 1. Characterize the immunogenicity of VLV-Multi-Ag constructs in mice. Aim 2. Evaluate vaccine efficacy in a lethal influenza mouse model. Aim 3. Evaluate prime-boost regimens to optimize flu-specific immune responses. The results of these studies will provide initial data on the feasibility of developing a UIV. VLV-mediated delivery of multi-antigens targeting multiple epitopes of conserved proteins may provide an effective strategy to prevent infection with influenza virus. The proposed research is highly significant because an effective vaccine is needed to prevent both influenza epidemics and to enhance our ability to respond to future pandemics.", "keywords": [ "Address", "Alphavirus", "Antibodies", "Antibody Response", "Antigen Targeting", "Antigens", "Automobile Driving", "Biological Assay", "Body Weight decreased", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "Cells", "Cellular Immunity", "Cessation of life", "Cyclic GMP", "Data", "Disease", "Disease Progression", "Dose", "Engineering", "Enzyme-Linked Immunosorbent Assay", "Epidemic", "Epitopes", "Failure", "Future", "GTP-Binding Proteins", "Gene Expression", "Goals", "Head", "Health", "Hemagglutinin", "Hepatitis B Antigens", "Hepatitis B Vaccines", "Hepatitis B Virus", "Hospitalization", "Human", "Hybrids", "IgG1", "Immune response", "Immunity", "Immunization", "Immunize", "Immunodominant Epitopes", "Immunoglobulin G", "Immunotherapeutic agent", "Immunotherapy", "In Vitro", "Individual", "Infection", "Infection prevention", "Influenza", "Influenza A Virus H3N2 Subtype", "Liver", "Lung", "Measures", "Mediating", "Messenger RNA", "Mus", "National Institute of Allergy and Infectious Disease", "Nucleoproteins", "Open Reading Frames", "Peptide Signal Sequences", "Peptides", "Persons", "Phenotype", "Proteins", "Publishing", "RNA", "RNA amplification", "Recombinant Proteins", "Regimen", "Replicon", "Research", "Respiratory Disease", "Serology", "Serotyping", "Specificity", "Stains", "T cell response", "T-Lymphocyte", "Technology", "Testing", "United States National Institutes of Health", "Vaccination", "Vaccines", "Vesicle", "Vesicular stomatitis Indiana virus", "Vesiculovirus", "Viral", "Viral Antigens", "Virus", "alpha helix", "base", "coronavirus vaccine", "enzyme linked immunospot assay", "flu", "immunogenic", "immunogenicity", "improved", "influenza epidemic", "influenza infection", "influenza virus strain", "influenza virus vaccine", "influenzavirus", "innovation", "interest", "mortality", "mouse model", "neutralizing antibody", "novel", "pandemic disease", "pandemic influenza", "plasmid DNA", "prevent", "rational design", "respiratory", "screening", "success", "universal influenza vaccine", "vaccine development", "vaccine efficacy", "vaccine evaluation", "vaccine platform", "vector", "vector vaccine", "virus development" ], "approved": true } }, { "type": "Grant", "id": "12358", "attributes": { "award_id": "1R56DE033249-01", "title": "Mechanisms of Immune Dysfunction in Oral Post-Acute Sequelae of Covid-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 22517, "first_name": "Preethi", "last_name": "Chander", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-13", "end_date": "2024-09-12", "award_amount": 581037, "principal_investigator": { "id": 28282, "first_name": "Afsar Raza", "last_name": "Naqvi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28283, "first_name": "Justin", "last_name": "Richner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28284, "first_name": "DEEPAK", "last_name": "SHUKLA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28285, "first_name": "Joel L", "last_name": "Schwartz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 163, "ror": "https://ror.org/02mpq6x41", "name": "University of Illinois at Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Coronavirus disease 2019 (Covid-19) is a viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infecting non-vaccinated and vaccinated people. Covid-19 clinically affects multiple organs including oral mucosa where SARS-CoV-2 replication occurs to deposit virion into saliva in sufficient copies (>1000) to be detected. Public health data reveals Covid-19 and periodontitis disproportionally affects Non-Hispanic Blacks (NHB) and Hispanics (H). We hypothesize that periodontal disease (PD) pre- conditions oral mucosa for persistent oral pathology and oral Post-Acute Sequelae of Covid-19 (PASC). However, the cellular and molecular mechanisms underlying this relationship between Covid-19 and poor oral health outcomes are unclear. Extending our preliminary dataset of oral examination, and immune assessment of Black and Hispanic cohort, our Aim 1 involves a comparative analysis of the impact of vaccination on oral PASC indicators and perturbation in oral immune surveillance. We assessed this relationship before vaccination was available, which provides an opportunity to compare how periodontal health, Covid-19 infection, and the vaccination status affects minority population (NHB/H) versus Non-Hispanic White (NHW) with similar variables and risk for oral PASC. Saliva and gingival crevicular fluid (GCF) will be examined to perform comprehensive profiling of immune cells (both myeloid and lymphoid compartments) and assess mediators of immune cell activation, polarization and exhaustion contributing to impaired oral immunity. We will decipher three important gaps of knowledge in an underserved cohort: (1) whether infectivity of SARS-CoV-2 is affected by poor oral health?, (2) does Covid-19-induced inflammation worsen pre-existing periodontal health, and (3) does Covid-19 vaccination lessen oral PASC viz. periodontal inflammation? In Aim 2, we will examine whether previous intracellular periopathogens enhance risk for continual reinfection of SARS-CoV-2 and promote oral PASC. Our lab has optimized an in vitro infection model of SARS-CoV-2 in primary gingival epithelial cells (GEC) to dissect the role of periodontal pathogens (both bacteria and herpesviruses) enhancing viral tropism and replication. Characterizing periodontal microbe-SARS-CoV-2 interaction will unravel novel mechanisms that can be targeted to mitigate oral PASC. Our findings will support that periodontal pathogens increase host susceptibility to SARS- CoV-2 infection by providing a conducive microenvironment for viral tropism, and persistence. Next, we will decipher SARS-CoV-2-mediated mechanisms of impairing periodontal immunity. To this end, we will characterize the novel role of SARS-CoV-2- open reading frames (ORFs) in modulating oral antiviral and antibacterial immunity by examining viral entry and replication, expression of Pathogen Recognition Receptor (PRR) and downstream signaling activation. Successful outcomes of this study will disclose novel relationships between Covid-19 and PD as well as intracellular periodontal bacteria and viruses viz., SARS-CoV-2 and herpesviruses. Identification of pathogenic factors that promote SARS-CoV-2 oral tropism could serve as novel therapeutic targets to suppress oral PASC signs and symptoms.", "keywords": [ "2019-nCoV", "ACE2", "Actinobacillus actinomycetemcomitans", "Adherence", "Affect", "Anti-Bacterial Agents", "Attenuated", "Bacteria", "Biological Response Modifiers", "Biopsy", "Black Populations", "Black race", "COVID-19", "COVID-19 risk", "COVID-19 susceptibility", "COVID-19 vaccination", "Cells", "Chronic", "Clinical", "Clinical Research", "Cytomegalovirus", "Data Set", "Deposition", "Epithelial Cells", "Exhibits", "Forsythia", "Gingiva", "Gingival Crevicular Fluid", "Health", "Herpesviridae", "Hispanic", "Hispanic Populations", "Hospitalization", "Human", "Human Herpesvirus 4", "Human body", "Immune", "Immune System Diseases", "Immune response", "Immunity", "Immunologic Surveillance", "Immunologics", "Immunologist", "Impairment", "In Vitro", "Infection", "Inflammation", "Inflammatory Infiltrate", "Innate Immune Response", "Knowledge", "Lymphoid", "Mediating", "Metalloproteases", "Microbe", "Minority Groups", "Modeling", "Molecular", "Mouth Diseases", "Mucosal Immunity", "Myelogenous", "Not Hispanic or Latino", "Open Reading Frames", "Oral", "Oral Examination", "Oral Pathology", "Oral health", "Oral mucous membrane structure", "Organ", "Outcome", "Outcome Study", "Pathway interactions", "Peptide Hydrolases", "Periodontal Diseases", "Periodontitis", "Population", "Porphyromonas gingivalis", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Prevalence", "Prospective cohort", "Public Health", "Recording of previous events", "Regulatory T-Lymphocyte", "Risk", "Risk Factors", "Role", "SARS-CoV-2 infection", "Saliva", "Salvia", "Scientist", "Signal Transduction", "Signs and Symptoms", "Surface", "Tooth structure", "Tropism", "Vaccinated", "Vaccination", "Vaccinee", "Viral", "Virion", "Virulence Factors", "Virus", "Virus Diseases", "Virus Replication", "Work", "Zoonoses", "anergy", "cohort", "comparative", "coronavirus disease", "ds-DNA", "exhaustion", "health data", "high risk population", "immune activation", "improved", "inflammatory marker", "inhibitor", "keratinocyte", "leukotoxin", "new therapeutic target", "novel", "oral condition", "oral immunity", "oral tissue", "pathogen", "periodontopathogen", "periopathogen", "pre-pandemic", "racial disparity", "racial health disparity", "receptor", "receptor expression", "screening", "synergism", "underserved community", "unvaccinated" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1424, "count": 14236 } } }